Antonio Jesús Banegas-Luna

Dr. Antonio Jesús Banegas-Luna

Universidad Católica San Antonio de Murcia, Murcia, Spain
orcid
Assistant Professor at Centro Universitario de la Defensa de...

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2019 in Molecules
Verified
Journal Article
Open access
PDF file
APAndreia Pereira
Andreia Pereira
Antonio Jesús Banegas-LunaAntonio Jesús Banegas-Luna
Antonio Jesús Banegas-Luna
JPJorge Peña-García
Jorge Peña-García
HPHoracio Perez-Sanchez
Horacio Perez-Sanchez
ZAZeno Apostolides
Zeno Apostolides
Culinary herbs and spices are widely used as a traditional medicine in the treatment of diabetes and its complications, and there are several scientific studies in the literature supporting the use of these medicinal plants. However, there is often a lack of knowledge on the bioactive compounds of these herbs and spices and their mechanisms of action. The aim of this study was to use inverse virtual screening to provide insights into the bioactive compounds of common herbs and spices, and their potential molecular mechanisms of action in the treatment of diabetes. In this study, a library of over 2300 compounds derived from 30 common herbs and spices were screened in silico with the DIA-DB web server against 18 known diabetes drug targets. Over 900 compounds from the herbs and spices library were observed to have potential anti-diabetic activity and liquorice, hops, fennel, rosemary, and fenugreek were observed to be particularly enriched with potential anti-diabetic compounds. A large percentage of the compounds were observed to be potential polypharmacological agents regulating three or more anti-diabetic drug targets and included compounds such as achillin B from yarrow, asparasaponin I from fenugreek, bisdemethoxycurcumin from turmeric, carlinoside from lemongrass, cinnamtannin B1 from cinnamon, crocin from saffron and glabridin from liquorice. The major targets identified for the herbs and spices compounds were dipeptidyl peptidase-4 (DPP4), intestinal maltase-glucoamylase (MGAM), liver receptor homolog-1 (NR5A2), pancreatic alpha-amylase (AM2A), peroxisome proliferator-activated receptor alpha (PPARA), protein tyrosine phosphatase non-receptor type 9 (PTPN9), and retinol binding protein-4 (RBP4) with over 250 compounds observed to be potential inhibitors of these particular protein targets. Only bay leaves, liquorice and thyme were found to contain compounds that could potentially regulate all 18 protein targets followed by black pepper, cumin, dill, hops and marjoram with 17 protein targets. In most cases more than one compound within a given plant could potentially regulate a particular protein target. It was observed that through this multi-compound-multi target regulation of these specific protein targets that the major anti-diabetic effects of reduced hyperglycemia and hyperlipidemia of the herbs and spices could be explained. The results of this study, taken together with the known scientific literature, indicated that the anti-diabetic potential of common culinary herbs and spices was the result of the collective action of more than one bioactive compound regulating and restoring several dysregulated and interconnected diabetic biological processes.

30 November 2018 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
Antonio Jesús Banegas-LunaAntonio Jesús Banegas-Luna
Antonio Jesús Banegas-Luna
José Pedro Cerón-CarrascoJosé Pedro Cerón-Carrasco
José Pedro Cerón-Carrasco
HPHoracio Perez-Sanchez
Horacio Perez-Sanchez
Virtual screening has become a widely used technique for helping in drug discovery processes. The key to this success is its ability to aid in the identification of novel bioactive compounds by screening large molecular databases. Several web servers have emerged in the last few years supplying platforms to guide users in screening publicly accessible chemical databases in a reasonable time. In this review, we discuss a representative set of online virtual screening servers and their underlying similarity algorithms. Other related topics, such as molecular representation or freely accessible databases are also treated. The most relevant contributions to this review arise from critical discussions concerning the pros and cons of servers and algorithms, and the challenges that future works must solve in a virtual screening framework. Graphical abstract

Verified
Journal Article
Open access
PDF file
Antonio Jesús Banegas-LunaAntonio Jesús Banegas-Luna
Antonio Jesús Banegas-Luna
JPJorge Peña-García
Jorge Peña-García
Adrian IfteneAdrian Iftene
Adrian Iftene
Fiorella GuadagniFiorella Guadagni
Fiorella Guadagni
Patrizia FerroniPatrizia Ferroni
Patrizia Ferroni
HPHoracio Perez-Sanchez
Horacio Perez-Sanchez
Artificial Intelligence is providing astonishing results, with medicine being one of its favourite playgrounds. Machine Learning and, in particular, Deep Neural Networks are behind this revolution. Among the most challenging targets of interest in medicine are cancer diagnosis and therapies but, to start this revolution, software tools need to be adapted to cover the new requirements. In this sense, learning tools are becoming a commodity but, to be able to assist doctors on a daily basis, it is essential to fully understand how models can be interpreted. In this survey, we analyse current machine learning models and other in-silico tools as applied to medicine—specifically, to cancer research—and we discuss their interpretability, performance and the input data they are fed with. Artificial neural networks (ANN), logistic regression (LR) and support vector machines (SVM) have been observed to be the preferred models. In addition, convolutional neural networks (CNNs), supported by the rapid development of graphic processing units (GPUs) and high-performance computing (HPC) infrastructures, are gaining importance when image processing is feasible. However, the interpretability of machine learning predictions so that doctors can understand them, trust them and gain useful insights for the clinical practice is still rarely considered, which is a factor that needs to be improved to enhance doctors’ predictive capacity and achieve individualised therapies in the near future.

1 January 2021 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
Qifeng BaiQifeng Bai
Qifeng Bai
JMJian Ma
Jian Ma
SLShuo Liu
Shuo Liu
TXTingyang Xu
Tingyang Xu
Antonio Jesús Banegas-LunaAntonio Jesús Banegas-Luna
Antonio Jesús Banegas-Luna
XYXiaojun Yao
Xiaojun Yao
Artificial intelligence can train the related known drug data into deep learning models for drug design, while classical algorithms can design drugs through established and predefined procedures. Both deep learning and classical algorithms have their merits for drug design. Here, the webserver WADDAICA is built to employ the advantage of deep learning model and classical algorithms for drug design. The WADDAICA mainly contains two modules. In the first module, WADDAICA provides deep learning models for scaffold hopping of compounds to modify or design new novel drugs. The deep learning model which is used in WADDAICA shows a good scoring power based on the PDBbind database. In the second module, WADDAICA supplies functions for modifying or designing new novel drugs by classical algorithms. WADDAICA shows better Pearson and Spearman correlations of binding affinity than Autodock Vina that is considered to have the best scoring power. Besides, WADDAICA supplies a friendly and convenient web interface for users to submit drug design jobs. We believe that WADDAICA is a useful and effective tool to help researchers to modify or design novel drugs by deep learning models and classical algorithms. WADDAICA is free and accessible at https://bqflab.github.io or https://heisenberg.ucam.edu:5000.

17 November 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
CPChristina Papaemmanouil
Christina Papaemmanouil
JPJorge Peña-García
Jorge Peña-García
Antonio Jesús Banegas-LunaAntonio Jesús Banegas-Luna
Antonio Jesús Banegas-Luna
AKAndroniki D. Kostagianni
Androniki D. Kostagianni
Ioannis GerothanassisIoannis Gerothanassis
Ioannis Gerothanassis
ATAndreas Tzakos
Andreas Tzakos
Natural products bear a multivariate biochemical profile with antioxidant, anti-inflammatory, antibacterial, and antitumoral properties. Along with their natural sources, they have been widely used both as anti-aging and anti-melanogenic agents due to their effective contribution in the elimination of reactive oxygen species (ROS) caused by oxidative stress. Their anti-aging activity is mainly related to their capacity of inhibiting enzymes like Human Neutrophil Elastase (HNE), Hyaluronidase (Hyal) and Tyrosinase (Tyr). Herein, we accumulated literature information (covering the period 1965–2020) on the inhibitory activity of natural products and their natural sources towards these enzymes. To navigate this information, we developed a database and server termed ANTIAGE-DB that allows the prediction of the anti-aging potential of target compounds. The server operates in two axes. First a comparison of compounds by shape similarity can be performed against our curated database of natural products whose inhibitory potential has been established in the literature. In addition, inverse virtual screening can be performed for a chosen molecule against the three targeted enzymes. The server is open access, and a detailed report with the prediction results is emailed to the user. ANTIAGE-DB could enable researchers to explore the chemical space of natural based products, but is not limited to, as anti-aging compounds and can predict their anti-aging potential. ANTIAGE-DB is accessed online.

29 April 2020 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
SPSavíns Puertas-Martín
Savíns Puertas-Martín
Antonio Jesús Banegas-LunaAntonio Jesús Banegas-Luna
Antonio Jesús Banegas-Luna
MPMaría Paredes-Ramos
María Paredes-Ramos
JRJuana L. Redondo
Juana L. Redondo
Pilar M. OrtigosaPilar M. Ortigosa
Pilar M. Ortigosa
HPHoracio Perez-Sanchez
Horacio Perez-Sanchez
(2020). Is high performance computing a requirement for novel drug discovery and how will this impact academic efforts?. Expert Opinion on Drug Discovery. Ahead of Print.